Syncromune, Inc.
Syncromune is a clinical-stage biopharmaceutical company dedicated to developing innovative combination immunotherapies for metastatic solid tumor cancers. Their mission is to develop a personalized in situ immunotherapy platform that synchronizes tumor antigens, immune cells, and biologic drugs to activate the immune system and attack cancer throughout the body. They focus on addressing unmet needs in cancers such as metastatic prostate, lung, and breast cancers, with a goal of achieving high response rates and potentially curative outcomes.
Industries
Nr. of Employees
small (1-50)
Syncromune, Inc.
Products
Personalized in situ combination immunotherapy platform
A platform approach that combines localized partial tumor oncolysis with intratumoral infusion of a multi-target biologic to synchronise tumor antigens, immune cells and immunomodulators in the tumor microenvironment.
Intratumoral combination biologic candidate for mCRPC (SV-102)
An investigational, intratumorally delivered multi-agent biologic regimen evaluated in early-phase trials for metastatic castration-resistant prostate cancer; used in combination with localized tumor lysis.
Personalized in situ combination immunotherapy platform
A platform approach that combines localized partial tumor oncolysis with intratumoral infusion of a multi-target biologic to synchronise tumor antigens, immune cells and immunomodulators in the tumor microenvironment.
Intratumoral combination biologic candidate for mCRPC (SV-102)
An investigational, intratumorally delivered multi-agent biologic regimen evaluated in early-phase trials for metastatic castration-resistant prostate cancer; used in combination with localized tumor lysis.
Services
Early-phase oncology clinical trial conduct
Design and conduct of Phase 1 investigator-initiated and Phase 2a dose-escalation and dose-optimization trials for intratumoral combination immunotherapies.
Investigator collaboration and site support
Operational support for investigator-initiated studies and multi-site activation, including coordination with clinical sites and academic partners.
Regulatory filing and engagement support
Preparation and submission of regulatory filings and engagement with regulatory agencies to obtain clearances and designations for investigational oncology therapies.
Early-phase oncology clinical trial conduct
Design and conduct of Phase 1 investigator-initiated and Phase 2a dose-escalation and dose-optimization trials for intratumoral combination immunotherapies.
Investigator collaboration and site support
Operational support for investigator-initiated studies and multi-site activation, including coordination with clinical sites and academic partners.
Regulatory filing and engagement support
Preparation and submission of regulatory filings and engagement with regulatory agencies to obtain clearances and designations for investigational oncology therapies.
Expertise Areas
- Intratumoral immunotherapy
- Combination multi-target immunotherapy
- Early-phase oncology clinical development
- Drug–device combination therapeutics
Key Technologies
- Cryoablation-mediated tumor lysis
- Intratumoral biologic infusion
- Drug–device combination delivery systems
- Multi-target immunomodulatory cocktails